RDPTF Radiopharm Theranostics Ltd

NEUTRAL Impact: 2/10 6-K
Horizon immediate Filed Jun 3, 2026 Processed 1d 12h ago SEC 0001213900-26-064446
Notable filing: 6-K
Latest settled — T+1d
RDPTF ▲ 0.00% at T+1d
NEUTRAL call ✗ call lost 0.00% · α vs SPY -0.40% · entry $0.0200 → $0.0200
Next anchor: T+5d in 4d
Currently $0.0200 · -0.00% from $0.0200 entry
Entry anchored
Jun 3, 2026
via day open
T+1d
0.00%
call 0.00% · α -0.40%
$0.0200
settled 2d ago
T+5d
call — · α —
in 4d
T+20d
call — · α —
in 26d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Radiopharm Theranostics filed a Form 6-K reporting the expiry of 505,598 unquoted options (RADAN) without exercise or conversion as of May 31, 2026. This is a routine administrative notification of a minor reduction in potential dilution — the ceased securities represent less than 0.1% of total outstanding shares and options. No material financial or operational impact.

Actionable Insight

No trading action warranted. This is a routine ASX Appendix 3H notification of option expiry with immaterial scale. Monitor the company's upcoming quarterly activities and pipeline catalysts for any material developments.

Key Facts

  • 505,598 unquoted options (RADAN) expired unexercised on May 31, 2026
  • No consideration paid by the company for the cessation
  • Total ordinary shares outstanding: 3,544,216,160; total options outstanding across all series: ~2.5 billion
  • Ceased options represent less than 0.02% of total ordinary shares outstanding

Financial Impact

Negligible — 505,598 options expired, representing less than 0.02% of the 3.54 billion ordinary shares outstanding. No cash consideration involved.

dilution

Risk Factors

  • Massive existing option overhang (~2.5 billion options vs 3.54 billion shares) could create future dilution if exercised
  • Historical performance shows zero stock movement on prior filings — low liquidity OTC stock with limited price discovery

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (6 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-064446
Document: ea0293413-6k_radiopharm.htm0001213900-26-064446
Document: 0001213900-26-064446-index-headers.html0001213900-26-064446
Document: 0001213900-26-064446-index.html0001213900-26-064446
Document: 0001213900-26-064446.txt0001213900-26-064446
8 reports for RDPTF
Performance horizon
0% Hit rate 0 of 4 directional calls best @ T+1· 0.00%Mar 27, 2026
Filters
Rows
Reports for RDPTF — sortable, filterable
Type Now
Jun 3, 2026
3d ago
6-K
NEUTRAL ★ 2/10
$0.0200 $0.0200· 0.00%▼ −0.40%$0.0200 (−0.00%)
May 7, 2026
4w ago
3
NEUTRAL ★ 2/10
$0.0200 $0.0200· 0.00%▼ −0.83%$0.0200 (−0.00%)
Apr 23, 2026
6w ago
6-K
MIXED ★ 5/10
$0.0200 $0.0200· 0.00%▼ −0.78%$0.0200 (−0.00%)
Apr 16, 2026
7w ago
6-K
BULLISH ★ 7/10
$0.0200 $0.0200· 0.00%▼ −1.21%$0.0200 (−0.00%)
Apr 8, 2026
8w ago
6-K
BULLISH ★ 6/10
$0.0200 $0.0200· 0.00%▼ −0.57%$0.0200 (−0.00%)
Apr 7, 2026
8w ago
6-K
BULLISH ★ 7/10
$0.0200 $0.0200· 0.00%▼ −2.54%$0.0200 (−0.00%)
Apr 2, 2026
9w ago
3
NEUTRAL ★ 3/10
$0.0200 $0.0200· 0.00%▼ −0.48%$0.0200 (−0.00%)
Mar 27, 2026
10w ago
6-K
BULLISH ★ 7/10
$0.0200 $0.0200· 0.00%▲ +0.36%$0.0200 (−0.00%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (14h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access